Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESS trial in adjuvant early breast cancer
2005-000490-21Phase 3Active
- Sponsor
- Frauenklinik der LMU
- Start
- Apr 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, gemcitabine, zoledronate, epirubicin, fluorouracil and 1 more in breast cancer (4 arms), sponsored by Frauenklinik der LMU. Primary endpoints: Time to recurrence for chemotherapy comparison and Time to recurrence for zoledronate duration comparison. Started Apr 2005; status: active.
02
Drugs
docetaxelgemcitabinezoledronateepirubicinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000490-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000490-21.